MedWatch survey approved
This article was originally published in The Tan Sheet
Executive Summary
The Office of Management & Budget has approved FDA's online MedWatch customer satisfaction survey of health care trade groups and specialty organizations that voluntarily participate in the agency's MedWatch Partners program, the agency announces Aug. 16. FDA solicited comments in May on its proposed survey "about the utility of the FDA MedWatch safety alerts and monthly safety labeling changes" posted on the MedWatch website and sent to partner organizations for distribution to organization members, according to a Federal Register notice...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.